- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Q methodology.
Displaying page 1 of 1.
EudraCT Number: 2010-019925-33 | Sponsor Protocol Number: D4130C00003 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in ... | ||||||||||||||||||
Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) FI (Completed) SE (Completed) LT (Completed) EE (Completed) LV (Completed) CZ (Completed) FR (Completed) HU (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000394-21 | Sponsor Protocol Number: A6301094 | Start Date*: 2016-07-20 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN® (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES. | |||||||||||||
Medical condition: Acute treatment and secondary prophylaxis of recurrent VTE (venous thromboembolism) in children with or without cancer. | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) SI (Completed) PL (Completed) GB (Completed) DE (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001269-18 | Sponsor Protocol Number: D-IVa/D-IVb | Start Date*: 2013-12-19 |
Sponsor Name:Universitätsklinikum Ulm (AöR) | ||
Full Title: A multicenter phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs). | ||
Medical condition: Everolimus/ribociclib cohort (D-IVa): Postmenopausal female patients with hormone-receptor positive, HER2-negative metastatic breast cancer with HER2-negative circulating tumor cells (CTCs) and ind... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024137-22 | Sponsor Protocol Number: D4130C00004 | Start Date*: 2011-02-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepressa... | |||||||||||||
Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020140-36 | Sponsor Protocol Number: D4130C00005 | Start Date*: 2010-09-13 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of TC-5214 (S-mecamylamine) as an Adjunct to an Antidepress... | |||||||||||||
Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy. Complemento de un antidepresivo en pacientes con tras... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) SK (Completed) FR (Completed) BG (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022647-38 | Sponsor Protocol Number: P06107 | Start Date*: 2011-11-16 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar I Disorder (Protocol No. P06107) | |||||||||||||
Medical condition: Acute Manic or Mixed Episodes Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
